On March 28, the Future Medicine Center of Shenzhen University of Advanced Technology (hereinafter referred to as the "Future Medicine Center") was officially inaugurated, marking a key step for SUAT in the medical field and injecting new momentum into promoting future medicine development and cultivating top innovative medical talents.

The Future Medicine Center is clinically demand-oriented, focusing on frontier areas such as cell and gene, medicine-engineering integration, longevity medicine, and brain-like intelligence. Relying on the foundations of SUAT's Faculty of Pharmacy, Faculty of Life and Health Sciences, Faculty of Synthetic Biology, and Faculty of Biomedical Engineering, it is committed to closely integrating future medical technologies with clinical and translational medicine first, achieving clinical application and translation at the SUAT Affiliated Hospital, proactively planning research, application scenarios, and industrial development for future human medicine, and aiming to cultivate research-oriented medical talents with both the spirit of medical scientists and the capabilities of clinical physicians.

Academician of the Chinese Academy of Sciences Gu Ying was appointed Director of the Future Medicine Center. She is Director of the Laser Medicine Center at the PLA General Hospital, with long-term engagement in the application and research of lasers in clinical medicine. She pioneered vascular-targeted photodynamic therapy, developed the national Class 1.1 photodynamic new drug Hemoporfin, established tumor-targeted tomographic photodynamic therapy, and pioneered the new field of wearable non-invasive phototherapy. In addition, she led the formulation of China's first clinical technical operation norms and diagnostic guidelines for laser medicine, and has received numerous honors including the Academic Award from the International Society for Laser Medicine, the National Invention Award, and the China Youth Science and Technology Award.

Professor Xu Zhiming from the SUAT Faculty of Pharmacy was appointed Executive Director of the Future Medicine Center. He studied under Academician of the Chinese Academy of Sciences Wu Mengchao, known as the father of hepatobiliary surgery in China, and has conducted in-depth research in multiple areas such as liver transplantation, clinical diagnosis and treatment of primary liver cancer, and basic research on hepatobiliary tumors.

In the future, the SUAT Future Medicine Center will implement institutionalized and organized research, promote scientific research and technological innovation in the medical field, cultivate top innovative talents to meet the needs of future medicine development, continuously enhance influence and competitiveness in the future medicine field, advance China's medical undertakings, and make positive contributions to safeguarding the health and well-being of the people.

Participants in the inauguration ceremony included Wang Shuguo, President of Fuyao University of Science and Technology; Zhu Shoufei, Member of the Party Committee and Vice President of Nankai University; Shu Rong, Party Secretary and Deputy Director of the Innovation Academy for Microsatellites, Chinese Academy of Sciences; Bao Yungang, Deputy Director of the Institute of Computing Technology, Chinese Academy of Sciences; Wang Ying, Education Advisor of BGI Group; as well as SUAT Party Secretary Zhu Dijian, President Fan Jianping, Dean of the Institute of Cell and Gene Technology Kang Le, Provost Zhao Wei, and Assistant to the President Yang Fan.